A 62-year-old man has elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH), normal prolactin, normal estradiol, normal DHEA‑sulfate, and low total testosterone, low bioavailable testosterone, low sex hormone‑binding globulin (SHBG), and low free testosterone; how should primary hypogonadism be managed?

Primary Hypogonadism Management in a 62-Year-Old Man

This patient has primary (hypergonadotropic) hypogonadism and should be treated with testosterone replacement therapy (TRT) if he has symptoms consistent with testosterone deficiency and no contraindications. 1

Diagnostic Confirmation

The laboratory values confirm primary hypogonadism:

• Elevated LH (16.5) and FSH (22.4) indicate testicular failure with intact pituitary feedback
• Low total testosterone (173 ng/dL), bioavailable testosterone (62), and free testosterone (31) confirm biochemical hypogonadism
• Unusually low SHBG (20 nmol/L) suggests possible underlying metabolic conditions (obesity, insulin resistance, metabolic syndrome, or hypothyroidism) 1

The low SHBG is critical here—it typically increases with aging, so a low value at age 62 warrants investigation for metabolic comorbidities that may be contributing to functional hypogonadism overlaying the primary testicular failure 1.

Pre-Treatment Evaluation Required

Before initiating TRT, you must:

1. Assess for symptoms of hypogonadism (reduced libido, erectile dysfunction, decreased spontaneous erections, decreased energy, reduced muscle mass/strength, mood changes, fatigue) 1

2. Screen for absolute contraindications 2, 3:

   • Prostate or breast cancer
   • PSA >4 ng/mL (or >3 ng/mL in high-risk men)
   • Palpable prostate nodule/induration
   • Hematocrit >48-50%
   • Severe untreated obstructive sleep apnea
   • Uncontrolled heart failure
   • Recent MI or stroke (<6 months)

3. Evaluate for metabolic conditions causing the low SHBG:

   • BMI and waist circumference
   • Screen for type 2 diabetes/metabolic syndrome
   • Thyroid function tests
   • Consider hepatic function 1

4. Discuss fertility - TRT will suppress spermatogenesis and is contraindicated if fertility is desired. Unlike secondary hypogonadism where gonadotropin therapy can restore fertility, primary hypogonadism patients cannot achieve fertility restoration with any hormonal therapy 1, 2

Treatment Algorithm

Step 1: Address Underlying Metabolic Conditions First

If obesity or metabolic syndrome is present, initiate lifestyle modifications concurrently with consideration of TRT 1, 3:

• Weight loss through caloric restriction
• Regular physical activity
• These interventions alone produce modest testosterone increases (1-2 nmol/L) but are insufficient for primary hypogonadism
• However, combining lifestyle changes with TRT yields superior outcomes 1

Step 2: Initiate Testosterone Replacement Therapy

For primary hypogonadism, TRT is the only option since the testes cannot respond to gonadotropin stimulation 1.

Preferred initial formulation: Transdermal testosterone (gel or patch) 3:

• Allows dose titration
• Avoids supraphysiologic peaks
• Can be discontinued quickly if adverse effects occur
• Target mid-normal testosterone range during treatment

Alternative formulations include intramuscular injections, buccal patches, or subcutaneous pellets based on patient preference, cost, and tolerability 1, 2.

Step 3: Monitoring Protocol (First Year)

Standardized monitoring includes 2:

• At 3-6 months and 12 months:
  • Symptom assessment (sexual function, energy, mood)
  • Serum testosterone levels (timing depends on formulation)
  • Hematocrit (risk of polycythemia)
  • PSA and digital rectal exam (men >40 years)
  • Adverse effects evaluation
  • Treatment adherence

Critical Caveats

1. The low SHBG is atypical for a 62-year-old and strongly suggests metabolic dysfunction that requires concurrent management 1

2. Primary hypogonadism is permanent—this patient will require lifelong TRT if initiated 1

3. Fertility is not achievable with any therapy in primary hypogonadism, unlike secondary hypogonadism where gonadotropins can restore spermatogenesis 1

4. Evidence quality remains low-to-moderate for long-term benefits and safety of TRT, particularly regarding cardiovascular outcomes and prostate cancer risk 4, 3. The 2020 American College of Physicians guideline suggests against initiating TRT specifically for improving energy, vitality, physical function, or cognition in age-related low testosterone 4, though this applies more to functional/age-related hypogonadism than to clear-cut primary hypogonadism.

5. Sexual function improvement is the most reliable benefit of TRT in the short term; other benefits remain uncertain 3